Clinical trials: Multiple Organ Dysfunction

Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome

Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients

• Completed
• Age: All ages
• Phase 2
• Results posted

Hematopoietic stem cell transplantation (HCT)-associated thrombotic microangiopathy (TMA) is an understudied complication of HCT that significantly affects transplant related morbidity and mortality.

Conditions

Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome, Multiple Organ Dysfunction Syndrome

Trial name

NCT03518203

Testing

Eculizumab

Where

3 sites in United States

Volunteers

23 people

Sponsor

Children's Hospital Medical Center, Cincinnati